DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Questions
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://link.springer.com/article/10.2165/11313490-000000000-00000, but it redirected us to https://link.springer.com/article/10.2165/11313490-000000000-00000. The analysis below is for the second page.

Title[redir]:
Therapeutic Breast Cancer Vaccines | BioDrugs
Description:
Treatment of breast cancer in the adjuvant setting has changed rapidly over the last few years. In addition to improvements in chemotherapy, radiation, hormone manipulation, and surgery, immunotherapy has emerged as an effective adjunct for the treatment of breast cancer. Passive immunotherapeutic agents such as trastuzumab have been widely adopted as the standard of care for HER-2/neu overexpressing breast cancer. Vaccine therapy in the metastatic setting has yet to demonstrate clinical significance in a phase III testing. This may be due to the enhanced immunosuppressive effects demonstrated in the tumor microenvironment. Lack of co-stimulatory molecules, activation of the cytotoxic T-lymphocyte antigen-4 (CTLA-4), increased T regulatory cells as well as soluble immunosuppressive factors produced by the tumor contribute to the ineffectiveness of vaccine therapy. Based on these observations, there has been a shift towards treating patients with minimal residual disease and a high risk of relapse. In this adjuvant setting, immune mechanisms of tumor evasion are less formidable, and the use of vaccine therapy in these patients may offer a higher chance of clinical benefit. There are several different vaccine approaches, including the use of cell-based vaccines (autologous, allogeneic, or dendritic cell-based), tumor-associated peptide or protein vaccines, DNA vaccines, heat shock proteins, and recombinant technology using viral or bacterial vectors to enhance immunogenicity of vaccine preparations. This review summarizes principles involving vaccine formulation and antigen selection, followed by a brief synopsis of therapeutic vaccines given in the metastatic setting and possible reasons for their lack of efficacy. The current literature regarding vaccine development for the treatment of breast cancer in the adjuvant setting is also reviewed.

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don't see any clear sign of profit-making.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Doi.org has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

cancer, google, scholar, article, cas, pubmed, breast, vaccine, patients, vaccines, herneu, clin, clinical, immunol, tumor, peptide, metastatic, cells, oncol, adjuvant, cell, res, chemotherapy, phase, immune, dendritic, study, response, jul, setting, immunotherapy, therapy, rev, peoples, abstract, treatment, vaccination, immunother, trial, disis, immunity, highrisk, privacy, cookies, content, therapeutic, murray, trastuzumab, antigen, allogeneic,

Topics {✒️}

e75-specific tumor-lytic ctls month download article/chapter clustered stn-klh conjugate her2-positive breast cancer high-risk ductal carcinoma therapeutic dendritic-cell vaccine 2/neu peptide-based vaccines 2/neu protein-specific antibody ii-key hybrid preventive c-side chain variants established cell-mediated immunity oxidized mannan-muc1 [isrctn71711835] t-cell-mediated suppression cell-mediated antitumor responses cancer vaccine trials adenovector-mediated gene delivery article biodrugs aims breast cancer vaccines cytotoxic t-lymphocyte antigen-4 cell-based vaccines dendritic cell vaccines dna vaccines low-dose intravenous cyclophosphamide stage ii carcinoma full article pdf hla-a2 complex metastatic breast cancer peptide-specific cd8+ inflammatory breast cancer breast cancer vaccine privacy choices/manage cookies phase iii testing t-cell recognition existent t-cell t-cell immunity recombinant poxvirus vaccines adjuvant chemo-immunotherapy disis ml dendritic cell-based anti-tumor immunity ii-key peptides minimal residual disease breast medical oncology advanced cancer patients 2/neu oncogenic protein immunother 2005 jul–aug hybrid peptides induce peptide-based vaccine ii-key segment ii-key moiety

Questions {❓}

Breast cancer vaccines: promise for the future or pipe dream?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Therapeutic Breast Cancer Vaccines
         description:Treatment of breast cancer in the adjuvant setting has changed rapidly over the last few years. In addition to improvements in chemotherapy, radiation, hormone manipulation, and surgery, immunotherapy has emerged as an effective adjunct for the treatment of breast cancer. Passive immunotherapeutic agents such as trastuzumab have been widely adopted as the standard of care for HER-2/neu overexpressing breast cancer. Vaccine therapy in the metastatic setting has yet to demonstrate clinical significance in a phase III testing. This may be due to the enhanced immunosuppressive effects demonstrated in the tumor microenvironment. Lack of co-stimulatory molecules, activation of the cytotoxic T-lymphocyte antigen-4 (CTLA-4), increased T regulatory cells as well as soluble immunosuppressive factors produced by the tumor contribute to the ineffectiveness of vaccine therapy. Based on these observations, there has been a shift towards treating patients with minimal residual disease and a high risk of relapse. In this adjuvant setting, immune mechanisms of tumor evasion are less formidable, and the use of vaccine therapy in these patients may offer a higher chance of clinical benefit. There are several different vaccine approaches, including the use of cell-based vaccines (autologous, allogeneic, or dendritic cell-based), tumor-associated peptide or protein vaccines, DNA vaccines, heat shock proteins, and recombinant technology using viral or bacterial vectors to enhance immunogenicity of vaccine preparations. This review summarizes principles involving vaccine formulation and antigen selection, followed by a brief synopsis of therapeutic vaccines given in the metastatic setting and possible reasons for their lack of efficacy. The current literature regarding vaccine development for the treatment of breast cancer in the adjuvant setting is also reviewed.
         datePublished:2012-08-16T00:00:00Z
         dateModified:2012-08-16T00:00:00Z
         pageStart:277
         pageEnd:287
         sameAs:https://doi.org/10.2165/11313490-000000000-00000
         keywords:
            Breast Cancer
            Trastuzumab
            Major Histocompatibility Complex Class
            Adjuvant Setting
            Metastatic Setting
            Molecular Medicine
            Antibodies
            Cancer Research
            Pharmacotherapy
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.2165%2F11313490-000000000-00000/MediaObjects/40259_2012_23050277_Tab1.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.2165%2F11313490-000000000-00000/MediaObjects/40259_2012_23050277_Tab2.jpg
         isPartOf:
            name:BioDrugs
            issn:
               1179-190X
               1173-8804
            volumeNumber:23
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Nathan M. Shumway
               affiliation:
                     name:San Antonio Military Medical Center
                     address:
                        name:Department of Medicine, San Antonio Military Medical Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nuhad Ibrahim
               affiliation:
                     name:MD Anderson Cancer Center
                     address:
                        name:Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sathibalan Ponniah
               affiliation:
                     name:Uniformed Services of the Health Sciences
                     address:
                        name:Cancer Vaccine Development Program, United States Military Cancer Institute, Department of Surgery, Uniformed Services of the Health Sciences, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:George E. Peoples
               affiliation:
                     name:Uniformed Services of the Health Sciences
                     address:
                        name:Cancer Vaccine Development Program, United States Military Cancer Institute, Department of Surgery, Uniformed Services of the Health Sciences, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:James L. Murray
               affiliation:
                     name:MD Anderson Cancer Center
                     address:
                        name:Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Therapeutic Breast Cancer Vaccines
      description:Treatment of breast cancer in the adjuvant setting has changed rapidly over the last few years. In addition to improvements in chemotherapy, radiation, hormone manipulation, and surgery, immunotherapy has emerged as an effective adjunct for the treatment of breast cancer. Passive immunotherapeutic agents such as trastuzumab have been widely adopted as the standard of care for HER-2/neu overexpressing breast cancer. Vaccine therapy in the metastatic setting has yet to demonstrate clinical significance in a phase III testing. This may be due to the enhanced immunosuppressive effects demonstrated in the tumor microenvironment. Lack of co-stimulatory molecules, activation of the cytotoxic T-lymphocyte antigen-4 (CTLA-4), increased T regulatory cells as well as soluble immunosuppressive factors produced by the tumor contribute to the ineffectiveness of vaccine therapy. Based on these observations, there has been a shift towards treating patients with minimal residual disease and a high risk of relapse. In this adjuvant setting, immune mechanisms of tumor evasion are less formidable, and the use of vaccine therapy in these patients may offer a higher chance of clinical benefit. There are several different vaccine approaches, including the use of cell-based vaccines (autologous, allogeneic, or dendritic cell-based), tumor-associated peptide or protein vaccines, DNA vaccines, heat shock proteins, and recombinant technology using viral or bacterial vectors to enhance immunogenicity of vaccine preparations. This review summarizes principles involving vaccine formulation and antigen selection, followed by a brief synopsis of therapeutic vaccines given in the metastatic setting and possible reasons for their lack of efficacy. The current literature regarding vaccine development for the treatment of breast cancer in the adjuvant setting is also reviewed.
      datePublished:2012-08-16T00:00:00Z
      dateModified:2012-08-16T00:00:00Z
      pageStart:277
      pageEnd:287
      sameAs:https://doi.org/10.2165/11313490-000000000-00000
      keywords:
         Breast Cancer
         Trastuzumab
         Major Histocompatibility Complex Class
         Adjuvant Setting
         Metastatic Setting
         Molecular Medicine
         Antibodies
         Cancer Research
         Pharmacotherapy
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.2165%2F11313490-000000000-00000/MediaObjects/40259_2012_23050277_Tab1.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.2165%2F11313490-000000000-00000/MediaObjects/40259_2012_23050277_Tab2.jpg
      isPartOf:
         name:BioDrugs
         issn:
            1179-190X
            1173-8804
         volumeNumber:23
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Nathan M. Shumway
            affiliation:
                  name:San Antonio Military Medical Center
                  address:
                     name:Department of Medicine, San Antonio Military Medical Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nuhad Ibrahim
            affiliation:
                  name:MD Anderson Cancer Center
                  address:
                     name:Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sathibalan Ponniah
            affiliation:
                  name:Uniformed Services of the Health Sciences
                  address:
                     name:Cancer Vaccine Development Program, United States Military Cancer Institute, Department of Surgery, Uniformed Services of the Health Sciences, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:George E. Peoples
            affiliation:
                  name:Uniformed Services of the Health Sciences
                  address:
                     name:Cancer Vaccine Development Program, United States Military Cancer Institute, Department of Surgery, Uniformed Services of the Health Sciences, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:James L. Murray
            affiliation:
                  name:MD Anderson Cancer Center
                  address:
                     name:Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:BioDrugs
      issn:
         1179-190X
         1173-8804
      volumeNumber:23
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:San Antonio Military Medical Center
      address:
         name:Department of Medicine, San Antonio Military Medical Center, San Antonio, USA
         type:PostalAddress
      name:MD Anderson Cancer Center
      address:
         name:Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:Uniformed Services of the Health Sciences
      address:
         name:Cancer Vaccine Development Program, United States Military Cancer Institute, Department of Surgery, Uniformed Services of the Health Sciences, Bethesda, USA
         type:PostalAddress
      name:Uniformed Services of the Health Sciences
      address:
         name:Cancer Vaccine Development Program, United States Military Cancer Institute, Department of Surgery, Uniformed Services of the Health Sciences, Bethesda, USA
         type:PostalAddress
      name:MD Anderson Cancer Center
      address:
         name:Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Nathan M. Shumway
      affiliation:
            name:San Antonio Military Medical Center
            address:
               name:Department of Medicine, San Antonio Military Medical Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Nuhad Ibrahim
      affiliation:
            name:MD Anderson Cancer Center
            address:
               name:Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:Sathibalan Ponniah
      affiliation:
            name:Uniformed Services of the Health Sciences
            address:
               name:Cancer Vaccine Development Program, United States Military Cancer Institute, Department of Surgery, Uniformed Services of the Health Sciences, Bethesda, USA
               type:PostalAddress
            type:Organization
      name:George E. Peoples
      affiliation:
            name:Uniformed Services of the Health Sciences
            address:
               name:Cancer Vaccine Development Program, United States Military Cancer Institute, Department of Surgery, Uniformed Services of the Health Sciences, Bethesda, USA
               type:PostalAddress
            type:Organization
      name:James L. Murray
      affiliation:
            name:MD Anderson Cancer Center
            address:
               name:Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Medicine, San Antonio Military Medical Center, San Antonio, USA
      name:Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, USA
      name:Cancer Vaccine Development Program, United States Military Cancer Institute, Department of Surgery, Uniformed Services of the Health Sciences, Bethesda, USA
      name:Cancer Vaccine Development Program, United States Military Cancer Institute, Department of Surgery, Uniformed Services of the Health Sciences, Bethesda, USA
      name:Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(273)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

4.55s.